IMMUNIBY

Memory B cell immunity in chronic viral infection

Coordinatore	UNIVERSITAET BASEL    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	1˙499˙923 €
EC contributo	1˙499˙923 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-StG_20111109
Funding Scheme	ERC-SG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2018-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITE DE GENEVE  Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Dr. Nome: Alex Cognome: Waehry Email: send email Telefono: +41 22 379 75 60 Fax: +41 22 379 11 80	CH (GENEVE)	beneficiary	0.00
2	UNIVERSITAET BASEL  Organization address address: Petersplatz 1 city: BASEL postcode: 4003 contact info Titolo: Dr. Nome: Kurt Cognome: Kamber Email: send email Telefono: +41 61 267 28 33	CH (BASEL)	hostInstitution	1˙499˙923.00
3	UNIVERSITAET BASEL  Organization address address: Petersplatz 1 city: BASEL postcode: 4003 contact info Titolo: Prof. Nome: Daniel David Cognome: Pinschewer Email: send email Telefono: +41 79 6945121 Fax: +41 22 3795746	CH (BASEL)	hostInstitution	1˙499˙923.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'This project aims for a quantum leap in the understudied area of memory B cell immunity to chronic viral infection. It provides i) a landscape analysis of primary and memory B cell responses to chronic viral challenge, ii) investigates receptor hypermutation of memory B cells for broadened protection against viral escape variants, and iii) studies the role of memory CD4 T cells in augmenting memory B cell protection in chronic viral infection. Memory B cells represent a main pillar of immunological memory and account for long-term protection by the hepatitis B virus vaccine, the only one to afford protection against a persistent viral infection in humans. Yet our understanding of memory B cell immunity to chronic viral infection remains rudimentary, owing to a lack of advanced methodology and model systems for its investigation. My laboratory has developed a comprehensive set of tools to overcome these hurdles in the prototypic chronic infection model of lymphocytic choriomeningitis virus (LCMV) in mice. We have at hands the first LCMV-neutralizing monoclonal B cell receptor-expressing mouse (unpublished), and will collaborate with a world-leading lab in B cell biology to exploit their novel mouse model for in vivo tracing of polyclonal antigen-specific memory B cells. Combined with genetically engineered LCMV mutants, multi-parameter flow cytometry, state-of-the-art immunological methods, histopathology and deep sequencing of B cell receptor repertoires, these models will allow for unprecedented cell transfer and viral infection studies in vivo. Our leading expertise in LCMV molecular biology and immunology, combined with our partners’ expertise in B cell biology warrants for a high likelihood of success in this ambitious journey to virgin territory. We expect this project to provide a conceptual basis and incentive to successfully exploit memory B cell immunity in the battle against global hepatitis C virus and human immunodeficiency virus pandemics.'